Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, the Company has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.